目的    分析胃癌新辅助化疗后原发病灶病理学完全缓解（pathological complete response，pCR）病人的临床特征。方法    筛选北京大学肿瘤医院2001—2010年间胃癌新辅助化疗原发病灶pCR的11 例病人的临床资料，分析其临床特征。结果    11例病人治疗前均为局部进展期胃癌，10例应用FOLFOX类方案、1例应用SOX化疗方案。1例病人术后病理提示有淋巴结转移；FOLFOX类方案的pCR率不足5%，现临床评效手段CT及超声胃镜（EUS）对于pCR病人的评估准确率低（2/11）；所有病人至今均无病生存，提示预后好。 结论    从pCR角度判断，目前应用的胃癌新辅助化疗方案及临床评效手段有待改良。

Clinical characteristics of gastric cancer patients with pathological complete response following neoadjuvant chemotherapy: an analysis of 11 patients        LI Zi-yu*, YUAN Peng , TANG Lei , et al. *Department of Gastrointestinal Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China
Corresponding author: JI Jia-fu, E-mail：jiafuj@hotmail.com
Abstract    Objective    To analyze the clinical characteristics of gastric cancer patients with pathological complete response (pCR) following neoadjuvant chemotherapy. Methods    The clinical data of gastric cancer patients who had undergone neoadjuvant chemotherapy from 2001 to 2010 in Peking University Cancer Hospital were collected and eleven patients were found to be pCR with their primary lesion. Results    All the 11 patients were local advanced gastric cancer. Ten of them received the FOLFOX and the other one with SOX as their neoadjuvant regimen. One patient got lymph node metastasis in the pathological examination. The pCR rate of the patients with FOLFOX regimen was lower than 5%, and the accurate rate (2/11) of clinical evaluate method (CT/EUS) was insufficient. All the patients were live without disease, which suggested good prognosis. Conclusion    Based on the pCR, the neoadjuvant chemotherapy regimen and clinical evaluate method await modification.